What is BPC-157 (Oral)?
Oral BPC-157 formulation discussed for GI-first protocols; evidence remains limited.
Research Indications
Demonstrated acceleration of wound healing and soft tissue repair in research
Research shows beneficial effects on intestinal lining and GI function
Associated with reduced joint inflammation and improved mobility
May support faster recovery from muscle strains and exercise stress
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Starting Dose | 100 mcg | Once daily | Subcutaneous injection |
| Standard Dose | 250 mcg | Once daily | Subcutaneous injection |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove BPC-157 (Oral) vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.
Week 2–4
Improved tissue mobility and reduced discomfort. Early healing acceleration.
Week 4–8
Significant recovery milestones. Stronger tissue repair and functional improvement.
Week 8–12
Near-complete healing in many cases. Improved strength and tissue integrity.
Side Effects & Safety
- Generally well-tolerated in research settings
- Mild nausea with higher doses
- Injection site redness or discomfort
- Rare: Dizziness or lightheadedness
- Potential effect on blood pressure (monitor if hypertensive)
BPC-157 (Oral) is not FDA-approved and cannot be prepared by 503A compounding pharmacies. PeptIQ does not sell peptides or list vendors. Talk with a licensed clinician.
FDA Status & Regulatory Info
Oral BPC-157 formulation discussed for GI-first protocols; evidence remains limited.
Frequently Asked Questions
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
What 752 users report
Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 56% · Mixed 28% · Unfavorable overall 16%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 200–400 mcg
Reports span 10–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
How repeat users are trending
Among repeat reporters, 66% said they felt similar to their last entry, 42% more positive, and 16% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 16 days · Based on 165 repeat reporters
Share Your Experience
Rate BPC-157 (Oral) in the PeptIQ app and help the community make informed decisions.
Research References (4)
Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.
- Wiki study page →Source
PubMed
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
- Wiki study page →Source
PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
- Wiki study page →Source
PubMed
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions
Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011
- Wiki study page →Source
PubMed
Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions
Tlak Gajger I, Ribarić J, Smodiš Škerl M, et al. Journal of veterinary pharmacology and therapeutics. 2018
Wiki tools
Observational indexes and compare views for BPC-157 (Oral).
Often tracked with
Educational information only
This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.